

ARTICLE OPEN



Complications and outcomes following injection of foreign material into the male external genitalia for augmentation: a single-centre experience and systematic review

Karl H. Pang^{1,2}, Karen Randhawa³, Stanley Tang¹, Giuseppe Fallara¹, Athos Katelaris⁵, Fabio Castiglione⁴, Kamran Ahmed⁴, Gideon Blecher⁶, Nim Christopher¹, David J. Ralph¹, Asif Muneer^{1,7,8} and Hussain M. Alnajjar^{1,2}✉

© The Author(s) 2023

Injection of exogenous material into the penis and scrotum has been performed for augmentation purposes. Complications include cosmetic dissatisfaction, penile necrosis and lymphoedema. We report the complications and outcomes from a single centre with an updated systematic review of the literature. A retrospective review of all cases presenting with foreign substance injection into the genitalia, over a 10-year period was performed. Thirty-five patients with a mean (standard deviation (SD); range) age of 36.9 (±9.1; 22–61) years at presentation were included. The mean (SD; range) time between injection and presentation was 7.8 (±5.8; 1 day–20 years) years. The most common injected substance was silicone ($n = 16$, 45.7%) and liquid paraffin ($n = 8$, 22.9%). The penile shaft (94.3%) was the most injected site. The most common presentations were cosmetic dissatisfaction (57.1%) and pain and/or swelling (45.7%). Surgery was required in 32 (91.4%) cases. Primary procedures included local excision and primary closure ($n = 19$, 59.4%), circumcision ($n = 5$, 15.6%), excision with a split skin graft or a scrotal flap reconstruction ($n = 5$, 15.6%). Three (8.6%) patients presented with necrosis and required acute debridement. Overall, 18 patients had more than 1 procedure, and 8 patients required 3 or more procedures. A systematic search of the literature identified 887 articles of which 68 studies were included for analysis. The most common substance injected was paraffin (47.7%), followed by silicone (15.8%). The majority of patients (77.9%) presented with pain, swelling or penile deformity. 78.8% of the patients underwent surgical treatment, which included excision and primary closure with or without the use of skin grafts (85.1% of all procedures), the use of flaps (12.3%) and penile amputation ($n = 2$). Complications of foreign body injection into the male genitalia can be serious resulting in necrosis and autoamputation. Surgical intervention is often required to excise abnormal tissue to manage pain and improve cosmesis.

IJIR: Your Sexual Medicine Journal (2024) 36:498–508; <https://doi.org/10.1038/s41443-023-00675-8>

INTRODUCTION

Genitalia augmentation involving the penis and/or scrotum has been a topical and controversial subject for many years. The definition of a “short” or a “small-sized” penis is unclear and debatable [1]. The length and/or the girth of the penis may be augmented surgically and non-surgically, and there has been a rise in non-surgical injections of products into the penis for aesthetic purposes by patients themselves, unregulated injectors, aestheticians, who may or may not be clinicians [2–4].

Many injectable products have been used for penile augmentation. Common medical substances used include hyaluronic acid [5], polylactic acid [6], polymethylmethacrylate (PMMA) microspheres [7], autologous fat [8] and liquid silicone [9]; and some non-medical materials used, commonly injected by patients themselves usually without medical advice include, mineral oil (e.g., baby, mechanical and olive oil) [10, 11], vaseline [12] and

liquid paraffin [13, 14]. Complications may occur immediately following injections resulting in collection or abscess formation and sepsis, or may occur months and years later as a result of chronic sclerosing inflammation with patients presenting with pain, penile deformity, aesthetic dissatisfaction [13, 15, 16]. Various names of sclerosing inflammation after penile injection have been used interchangeably including, foreign body giant-cell granuloma, sclerosing lipogranuloma, or terms used associated with the product injected, such as paraffinoma, siliconoma and vaselinoma [13, 15].

Management depends on the timing and type of presentation and may include, debridement of necrotic tissue, primary excision of the product with primary closure, or reconstruction with skin graft and flaps [13, 15].

We previously reported a case series of 5 patients [10], here, we present the largest UK series to date reflecting our experience of

¹Department of Urology and Institute of Andrology, University College London Hospitals NHS Foundation Trust, London, UK. ²Division of Surgery and Interventional Science, University College London, London, UK. ³Department of Urology, Western Health and Social Care Trust, Ireland, UK. ⁴Department of Urology, King's College London Hospital NHS Foundation Trust, London, UK. ⁵Department of Urology, St George Hospital, Sydney, NSW, Australia. ⁶Department of Surgery, Monash University, Melbourne, VIC, Australia. ⁷NIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK. ⁸Department of Surgical Biotechnology, University College London, London, UK. ✉email: Hussain.alnajjar@nhs.net

Received: 3 November 2022 Revised: 27 January 2023 Accepted: 31 January 2023

Published online: 1 March 2023

Table 1. Patient demographics and clinical details.

Clinical details	n (%)
Age at presentation, mean (SD; range), years	36.9 (± 9.3 ; 22–61)
Follow-up, mean (SD; range), months	18.8 (± 25.7 ; 1–120)
Country of origin	
UK	14 (40.0)
Eastern Europe	13 (37.1)
Southeast Asia	6 (17.1)
Other Europe	2 (5.7)
Substance injected	
Silicone	16 (45.7)
Paraffin	8 (22.9)
Vaseline	4 (11.4)
Baby oil	3 (8.6)
Autologous fat	2 (5.7)
Marble	1 (2.9)
Unknown	1 (2.9)
Number of sites injected	
1	18 (51.4)
2	12 (34.3)
3	4 (11.4)
4	1 (2.9)
Injection site	
Penis shaft	33 (94.3)
Foreskin	11 (31.4)
Scrotum	11 (31.4)
Suprapubic area	2 (5.7)
Frenulum	1 (2.9)
Time from injection to presentation, mean (SD; range), years	7.8 (± 5.8 ; 0–20)
Clinical presentation	
Cosmetic dissatisfaction	20 (57.1)
Pain/swelling	16 (45.7)
Tight foreskin/phimosis	8 (22.9)
Necrosis	3 (8.6)

managing complications following genitalia injection of foreign material for augmentation. In addition, we provide an update of the literature via a systematic review.

MATERIALS AND METHODS

Patients

Following Institutional Review Board (IRB) approval, a retrospective review of all cases presenting with foreign substance injection into the genitalia during a 10-year period between 2010 and 2019 was performed at a single United Kingdom (UK) tertiary centre. Patients were identified through out-patient clinic, operative and histopathological databases. Data collected included patient demographics, type of substance injected, injection site, time between injection and presentation, symptoms at presentation, and management of complications. The study was reported in accordance with the STROBE checklist (Supplementary Table 1) [17].

Systematic review

The PubMed database was searched on August 13, 2022 (Supplementary Material 1). All English articles reporting on complications of genitalia injections for augmentation were included. All titles and abstracts were screened separately by two authors (KHP and ST) initially. Full-text articles

Table 2. Management of penile injection complications.

Management	n (%)
No. of procedures	
0 (conservative management)	3 (8.6)
1	14 (40.0)
2	10 (28.6)
3	6 (17.1)
4	1 (2.9)
5	1 (2.9)
Total no. procedures performed	61
Primary procedure (<i>n</i> = 32)	
Excision + primary closure ^a	19 (59.4)
Circumcision	5 (15.6)
Excision + SSG	4 (12.5)
Debridement necrotic tissue	3 (9.4)
Excision + scrotal flap	1 (3.1)
Subsequent procedures (<i>n</i> = 29)	
Excision + primary closure	19 (65.5)
Excision + SSG	3 (10.3)
Excision + scrotal flap	3 (10.3)
Circumcision	2 (6.9)
Scrotoplasty	1 (3.5)
Revision scar	1 (3.5)

SSG split skin graft.

^aTwo patients had a partial scrotoplasty.

of the included abstracts were further screened (KHP and ST). Any disagreements were solved by the two screeners, in cases where no agreement was made, the senior author (HMA) made the final decision. The references of the final list of included studies were also screened for eligibility.

RESULTS

Patients and complications

Overall, 35 patients, mean (SD; range) age of 36.9 (± 9.3 ; 22–61) years presented to our centre over 10 years. The mean (SD; range) follow-up was 18.8 (± 25.7 ; 1–120) months. Demographics, site of injection, the substance injected, and clinical presentations are detailed in Table 1. Overall, 29 (82.9%) men were from Europe, of which, 14 (48.3%) were from the UK and 13 (44.8%) were from Eastern Europe. The most commonly used product was silicone (*n* = 16, 45.7%). The most common site of injection was the penis, whereby 33 (94.3%) patients were injected into this area, of which 11 (31.4%) were also injected into their scrotum. Cosmetic dissatisfaction (*n* = 20, 57.1%) commonly associated with visible lumps and penile deformity was the most frequent presentation. The second most common presentation was pain and swelling (*n* = 16, 45.7%). Necrosis at presentation was identified in three (8.8%) patients. The mean (range) time between injection and presentation to our unit was 7.8 (1 day–20 years) years.

Management

Overall, 32 (91.4%) patients underwent surgery and the other 3 (8.6%) men were managed conservatively.

During the study period, 61 procedures were performed. Overall, 14 (40%) men had 1 procedure and 1 (2.9%) patient required 5 procedures in order to remove all the products and achieve cosmetic satisfaction (Table 2).




Fig. 1 Pre-, intra-, and post-operative images of selected cases. Consent was obtained for the use of photos. **1.1a** Penoscrotal oedema secondary to silicone injection; **1.1b** excision of scrotal silicone; **1.1c** 6 weeks post-operative appearance. **1.2a** Penile oedema secondary to paraffin injection; **1.2b** dissection of foreign material. **1.3a** Penile ulceration and deformity secondary to paraffin injection; **1.3b** excision of abnormal penile tissue; **1.3c** full-thickness skin graft preparation; **1.3d** completion of excision of abnormal penile tissue and reconstruction with skin graft. Patient is now pain-free and sexually active.




Fig. 2 Histopathological slide demonstrating sclerosing lipogranuloma. $\times 4$ magnification. Haematoxylin and Eosin stain. There is evidence of foreign body giant-cell reaction around lipid vacuoles and fat necrosis. Courtesy of Dr Aiman Haider, Consultant Urological Histopathologist, University College London Hospital NHS Foundation Trust. London, UK.

The primary procedures ($n = 32$) are detailed in Table 2. A total of 19 (58.4%) patients underwent excision of the abnormal tissue and injected product with primary closure (Fig. 1). Partial scrotoectomy was necessary in 5 of the 19 patients. The three patients who presented with tissue necrosis (penile, $n = 2$; scrotum, $n = 1$) underwent acute debridement. All three patients subsequently underwent deferred reconstruction with further excision of any residual product and scrotal flap coverage. Subsequent procedures ($n = 29$) included further excision of tissue and primary closure ($n = 19$, 65.5%); excision and split skin graft ($n = 3$, 10.3%); excision and scrotal flap ($n = 3$, 10.3%); scrotoplasty ($n = 1$, 3.5%) (Table 2). Out of the 61 procedures performed in our series, 38 (62.3%) were excision and closures, 7 (11.5%) procedures involved the use of a graft and 4 (6.6%) procedures required a scrotal flap.

Histopathological findings

Within the excised tissue, histopathological findings included deposits of lipid vacuoles embedded in sclerotic stroma with associated foreign body type giant-cell granuloma. Features were

Table 3. Summary of case reports and studies included in the current systematic review.

Author	Date	Country	Study design	No. of patients	Age (years)	Penis and scrotum	Substance	Presentation/complication	Time to presentation (year)	Surgical management	Conservative management	Follow-up (months)
Pang	2022	UK	Retrospective	35	36.9 (22–61)	11 (31.4)	Silicone	Pain	16 (45.7)	Excision + primary closure	3 (8.6)	18.8 (0–120)
							Paraffin	Cosmetic dissatisfaction	20 (57.0)	Circumcision	5 (15.6)	
							Vaseline	Tight foreskin/phimosis	7 (22.9)	Excision + SSG	4 (12.5)	
							Baby oil	Necrosis	2 (8.6)	Debridement necrotic tissue	3 (9.4)	
							Autologous fat		2 (5.7)	Excision + scrotal flap	1 (3.1)	
							Marble		1 (2.9)			
							Unknown		1 (2.9)			
Hrudka [18]	2022	Czech Republic	Case report	1	NR	0 (0)	Paraffin	NR	1 (100)	Excision + SSG	1 (33)	NR
Ismi [19]	2022	Indonesia	Case report	1	42	0 (0)	Paraffin	Pain	1 (100)	Excision + FTSG	1 (100)	24
								Erectile dysfunction	1 (100)			
								Penile deformity	1 (100)			
Pereira-Lorenzo [20]	2021	Spain	Case Report	1	50	0 (0)	Paraffin	Pain, cosmetic dissatisfaction	1 (100)	Excision + flap	1 (100)	3
Quan [5]	2021	China	Case series	10	30	0 (0)	Hyaluronic acid	Subcutaneous nodule	5 (50)	Incision and drainage	8 (80)	1–6
								Subcutaneous bleeding	3 (30)			
								Infection	2 (20)			
Khor [21]	2021	Australia	Case report	1	31	0 (0)	Hyaluronic acid	Pain	1 (100)		0 (0)	3
								Septic shock	1 (100)			
Yamasaki [22]	2021	Japan	Case report	1	65	0 (0)	Hyaluronic acid	Pain	1 (100)	Partial penectomy	1 (100)	NR
								Necrosis	1 (100)			
Boucher [23]	2021	France	Case series	10	NR	0 (0)	Silicone	Pain	7 (70)	Excision + flap	9 (90)	12
							Paraffin	Painful intercourse	3 (30)	Excision + FTSG	1 (10)	
Nabihah [11]	2021	Malaysia	Case report	1	50	0 (0)	Olive oil	Painful intercourse	1 (100)	Excision + SSG	1 (100)	1
								Swelling	1 (100)			
								Penile deformity	1 (100)			
Bryce [24]	2021	USA	Case report	1	56	0 (0)	Hyaluronic acid	Pain	1 (100)		0 (0)	1
								Swelling	1 (100)			
Vladislav [25]	2020	Bulgaria	Case report	1	38	0 (0)	Paraffin	Pain	1 (100)	Excision + SSG	1 (100)	3 w
								Erectile dysfunction	1 (100)			
								Penile deformity	1 (100)			
Downey [15]	2019	UK	Case series	3	NR	0 (0)	Paraffin	Pain	3 (100)	Excision + closure	2 (66.7)	NR
								Sepsis	1 (33.3)	Incision + drainage abscess	1 (33.3)	
Kim [14]	2019	Korea	Retrospective	23	45.3	2 (9)	Paraffin	Penile deformity	23 (100)	Excision + closure	23 (100)	12.2
Dellis [26]	2018	Greece	Case series	10	20–38	3 (30)	Paraffin	Pain, cosmetic dissatisfaction	5 (50)	Excision + flap	10 (100)	2
							Silicone		3 (30)			
							Vaseline		1 (10)			
							Olive oil		1 (10)			
Furr [27]	2018	USA	Case series	11	47 (21–77)	2 (18.2)	Silicone	Pain	7 (63.6)	Excision + closure	8 (72.7)	12
							Fat	Swelling	1 (9.1)	Excision + flap	1 (9.1)	
							Saline	Abscess	2 (18.2)	Debridement + SSG	1 (9.1)	
							Acellular dermis	Infection	1 (9.1)	Orchiectomy	1 (9.1)	
							Unknown	Nodules	1 (9.1)			

Table 3. continued

Author	Date	Country	Study design	No. of patients	Age (years)	Penis	Penis and scrotum	Substance	Presentation/ complication	Time to presentation (year)	Surgical management	Conservative management	Follow-up (months)
Favaret [28]	2018	Brazil	Case report	1	36	1 (100)	0 (0)	Mineral oil	Gangrene	1			
									Pain	1 (100)	1 (100)	0 (0)	3
									Mass	1 (100)	Excision + flap	1 (100)	
Svensoy [29]	2018	Thailand-Myanmar	Retrospective	680	32 (17–68)	Not reported	NR	NR	Ulcer	1 (100)			
									Pain	571 (84)	Surgical treatment	507 (74.6)	173 (25.4) NR
									Swelling	561 (82.5)	Circumcision	4 (0.6)	
									Induration	292 (42.9)	Excision ± graft	503 (74)	
									Purulent secretion	148 (22)			
									Ulceration	87 (12.8)			
Chon [30]	2017	Korea	Case report	1	64	1 (100)	0 (0)	Paraffin	Sexual dysfunction	1 (100)	Excision + scrotal flap	0 (0)	3
									Penile curvature	1 (100)			
									Voiding difficulty	1 (100)			
									Tight foreskin/ phimosis	1 (100)			
									Pain	1 (100)	Excision + closure	1 (100)	0 (0) Lost to FU
									Thickening of scrotum/prepuce	1 (100)		0 (0)	Refused treatment Lost to FU
Ahmed [10]	2017	UK	Case series	5	42.4 (28–61)	4 (80)	1 (20)	Baby oil	Pain	2 (40)	Debridement	1 (20)	0 (0) NR
									Swelling	2 (40)	Excision + closure	2 (40)	
									Voiding difficulty	1 (20)	Partial scroterectomy	1 (20)	
									Penile deformity	2 (40)	Refused surgery	1 (20)	
									Cosmetic dissatisfaction	1 (20)			
									Swelling	1 (100)			
Tsili [33]	2016	Greece	Case report	1	52	1 (100)	0 (0)	Silicone	Sexual dysfunction	1 (100)	Excision + closure	1 (100)	0 (0) 2
									Pain	1 (100)	Excision + closure	1 (100)	0 (0) 3
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 6w
Singh [34]	2015	Malaysia	Case report	1	32	1 (100)	0 (0)	Paraffin	Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 2
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 3
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 6w
Cormio [35]	2014	Italy	Case report	1	35	1 (100)	0 (0)	Paraffin	Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 6w
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 6w
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 6w
Francis [36]	2014	Singapore	Case series	4	22.5 (17–27)	4 (100)	0 (0)	Jamaica oil	Swelling	3 (75)	Excision + scrotal flap	1 (25)	2 (50) NR
									Swelling	3 (75)	Debridement	1 (25)	
									Swelling	3 (75)	Debridement	1 (25)	
Majedah [37]	2014	Malaysia	Case report	1	36	1 (100)	0 (0)	Paraffin	Swelling	1 (100)	Excision + closure	1 (100)	0 (0) NR
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) NR
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) NR
Gomez-Armayones [38]	2014	Spain	Case report	1	27	1 (100)	0 (0)	Unknown	Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 1 (100) Lost to FU
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 3
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 12
Kim [39]	2014	Korea	Case series	5	NR	5 (100)	0 (0)	Paraffin	Swelling	5 (100)	Excision + closure	5 (100)	0 (0) 3
									Swelling	5 (100)	Excision + closure	5 (100)	0 (0) 3
									Swelling	5 (100)	Excision + closure	5 (100)	0 (0) 3
De Slati [40]	2013	Italy	Case report	1	27	1 (100)	0 (0)	Paraffin	Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 12
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 12
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 12
Shin [41]	2013	Korea	Retrospective	34	47.4	28 (82.4)	6 (17.6)	Paraffin	Swelling	5 (14.7)	Excision + closure	34 (100)	0 (0) Mean, 13.5
									Swelling	5 (14.7)	Excision + closure	34 (100)	0 (0) Mean, 13.5
									Swelling	5 (14.7)	Excision + closure	34 (100)	0 (0) Mean, 13.5
Oanta [42]	2013	Romania	Case report	1	29	1 (100)	0	Kanamycin	Swelling	1 (100)	Excision + closure	1 (100)	0 (0) NR
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) NR
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) NR
Sukop [43]	2013	Czech Republic	Case report	1	36	1 (100)	0 (0)	Silicone	Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 3
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 3
									Swelling	1 (100)	Excision + closure	1 (100)	0 (0) 3

Table 3. continued

Author	Date	Country	Study design	No. of patients	Age (years)	Penis	Penis and scrotum	Substance	Presentation/complication	Time to presentation (year)	Surgical management	Conservative management	Follow-up (months)					
Shamsodini [9]	2012	Qatar	Case series	4	40 (30–45)	4 (100)	0 (0)	Silicone	Infection	2 (50)	Excision + delayed closure	2 (50)	0 (0)	NR				
Sejben [44]	2012	Hungary	Case report	1	34	1 (100)	0 (0)	Petroleum jelly	Painful intercourse	2 (50)	Excision + flap	2 (50)	NR					
									Pain	1 (100)				3	Excision	1 (100)	0 (0)	
									Penile deformity	1 (100)								
Bayraktar [45]	2012	Turkey	Case report	2	22.5 (19–22)	2 (100)		Paraffin	Inguinal lymphadenopathy	1 (100)	Excision + closure	2 (100)	0 (0)	24				
									Pain	2 (100)					5–6 d	Excision + closure	2 (100)	0 (0)
									Penile deformity	2 (100)								
Onate Celdran [46]	2012	Spain	Case report	1	32	1 (100)	0 (0)	Paraffin	Pain	1 (100)	Excision + closure	1 (100)	0 (0)	NR				
									Swelling	1 (100)					2	Excision + closure	1 (100)	0 (0)
Inn [47]	2012	Malaysia	Case series	3	45.7 (32–59)	3 (100)	0 (0)	Silicone	Pain	3 (100)	Excision + SSG	3 (100)	0 (0)	1				
Karakan [48]	2012	Turkey	Case report	1	42	1 (100)	0 (0)	Vaseline	Penile deformity	3 (100)	Excision + SSG	1 (100)	0 (0)	7 d				
									Swelling	3 (100)					1 m	Excision + SSG	1 (100)	0 (0)
Kadouch [49]	2012	Netherlands	Case series	3	45 (38–54)	2 (66)	1 (34)	Polyalkylimide	Lump	1 (100)	Excision + SSG	1 (33)	1 (33)	12				
									Infection	2 (66)					2–6 m	Excision + SSG	1 (33)	1 (33)
Bachmeyer [50]	2011	France	Case report	1	30	1 (100)	0 (0)	Paraffin	Pain	1 (33)	Excision + closure	1 (33)	0 (0)	Lost to FU				
									Pain	1 (100)					10	Excision + closure	1 (100)	0 (0)
									Swelling	1 (100)								
Manny [51]	2011	USA	Case report	3	43.3 (39–47)	3 (100)	0 (0)	Mineral oil	Pain	3 (100)	Excision + SSG	1 (33.3)	0 (0)	1–3				
									Pain	3 (100)					2 m–4 y	Excision + SSG	1 (33.3)	0 (0)
									Swelling	1 (33.3)						Excision + scrotal flap	1 (33.3)	
Foxton [52]	2011	Australia	Case report	1	25	1 (100)	0 (0)	Oil	Phimosis	1 (33.3)	Awaiting	1 (100)	0 (0)	NR				
									Penile deformity	3 (100)					1.5	Excision + closure	1 (33.3)	
									Penile deformity	1 (100)								
Bobik [53]	2011	Slovakia	Case report	1	33	1 (100)	0 (0)	Vaseline	Ulcers	1 (100)		0 (0)	1 (100)	NR				
Al-Ansari [54]	2010	Qatar	Case series	8	38.6 (28–50)	8 (100)	0 (0)	Cod liver oil	Infection	8 (100)	Scrotal debulking	2 (25)	0 (0)	NR				
															2 w			
Bjurlin [55]	2010	USA	Case report	1	35	1 (100)	0 (0)	Mineral oil	Excision + flap	5 (63)	Excision + closure	1 (12)	0 (0)	NR				
									Penile deformity	1 (100)					1	Excision + SSG	1 (100)	0 (0)
									Pain	1 (100)								
Ponyai [56]	2010	Hungary	Case report	1	29	1 (100)	0 (0)	Paraffin	Sexual dysfunction	1 (100)	Excision + SSG	1 (100)	0 (0)	NR				
									Pain	1 (100)					14	Excision + SSG	1 (100)	0 (0)
Picozzi [57]	2010	Italy	Case report	1	38	1 (100)	0 (0)	Paraffin	Lesion	1 (100)	Excision + closure	1 (100)	0 (0)	2 d				
									Swelling	1 (100)					2 d	Excision + closure	1 (100)	0 (0)
Shaeer [58]	2009	Egypt	Case report	1	28	1 (100)	0	Gel	Necrosis	1 (100)	Excision + closure	1 (100)	5 w					
									Paraphimosis	1 (100)								
									Cosmetic dissatisfaction	1 (100)				2	Excision + closure	1 (100)		
Silberstein [59]	2008	USA	Case report	1	61	1 (100)	0 (0)	Silicone	Painful intercourse	1 (100)		0 (0)	1 (100)	NR				
									Infection	1 (100)					10	Excision + SSG	4 (16)	2 (8)
	2008	Bulgaria	Retrospective	25		25 (100)	0 (0)	Paraffin	Swelling	1 (100)	Excision + SSG	4 (16)	2 (8)	NR				

Table 3. continued

Author	Date	Country	Study design	No. of patients	Age (years)	Penis and scrotum	Substance	Presentation/ complication	Time to presentation (year)	Surgical management	Conservative management	Follow-up (months)
Pehlivanov [60]					28.3 (19–40)							
							Firm, non-fluid	2 (8)	11 (47.8)	Excision + scrotal flap	5 (20)	
								Phimosis	2 (8.7)	Excision + closure	14 (56)	
								Fistula	3 (13)			
Nyirady [12]	2008	Hungary	Prospective	16	31.6 (22–44)	16 (100)	Vaseline	Pain	9 (56.3)	Excision + scrotal flap	7 (43.7)	24
								Swelling	11 (68.8)	Excision + closure	9 (56.3)	
								Necrosis	5 (31.3)			
								Phimosis	6 (37.5)			
Dachian [61]	2007	Indonesia	Case report	1	30	1 (100)	Silicone	Cosmetic dissatisfaction	1 (100)	Excision + closure	1 (100)	NR
Oh [62]	2007	Korea	Case report	1	72	1 (100)	Metallic mercury	Pain	1 (100)	Total penectomy, perineal urethrostomy	1 (100)	7
								Infection	1 (100)			
Lee [63]	2007	Korea	Case report	1	42	1 (100)	Petroleum jelly	Fournier's gangrene	1 (100)	Debridement + flap	1 (100)	14
Rosenberg [64]	2007	Israel	Case series	3	31 (28–35)	3 (100)	Oil	Pain	2 (66.6)	Incision paraphimotic ring	1 (33.3)	2.6 d (1–4 d)
								Swelling	3 (100)			
								Paraphimosis	1 (33.3)			
								Phimosis	1 (33.3)			
Eandi [65]	2007	USA	Case report	1	71	1 (100)	Unknown	Voiding difficulty	1 (100)	Excision + closure	1 (100)	12
								Pain	1 (100)			
								Penile deformity	1 (100)			
Akkus [66]	2006	Turkey	Case report	1	42	1 (100)	Vaseline	Lesion	1 (100)		0 (0)	3 w
								Penile deformity	1 (100)			
								ED	1 (100)			
Cavalcanti [67]	2006	Brazil	Case series	5	22–42	5 (100)	Silicone	Cosmetic dissatisfaction	5 (100)	Excision + graft	5 (100)	NR
Hohaus [68]	2003	Germany	Case report	1	30	1 (100)	Vaseline	Painful intercourse	1 (100)	Excision + flap	1 (100)	NR
Choudhury [69]	2003	UK	Case report	1	50	1 (100)	Baby oil	Necrosis	1 (100)	SSG	1 (100)	NR
								Swelling	1 (100)			
Santos [70]	2003	Portugal	Case report	1	40	1 (100)	Paraffin	Phimosis	1 (100)	Excision + closure	1 (100)	2
								Pain	1 (100)			
								Mass	1 (100)			
Cohen [71]	2002	USA	Case report	1	64	1 (100)	Mineral oil	Phimosis	1 (100)	Excision + closure	1 (100)	6
								ED	1 (100)			
								Voiding difficulty	1 (100)			
Kalsi [72]	2002	UK	Case report	1	31	1 (100)	Greece gun	ED	1 (100)	Excision + closure	1 (100)	6
Steffens [73]	2000	Germany	Case series	5	31.2 (27–40)	4 (80)	Vaseline	Penile deformity	1 (100)	Excision + graft	4 (80)	NR
								Cosmetic dissatisfaction	2 (40)			
								Painful intercourse	2 (40)			
Ciancio [74]	2000	USA	Case report	1	55	1 (100)	Mineral oil	Ulceration	1 (20)	Scrotal debulking	1 (20)	
								Pain	1 (100)	Excision + closure	1 (20)	
								Ulcerated mass – SCC (Bx)	1 (100)	Excision + SSG	1 (100)	6
Murato [75]	1996	Italy	Case report	1	32	1 (100)	Paraffin	Cosmetic dissatisfaction	1 (100)	Excision + flap	1 (100)	34
Wassermann [76]	1995	USA	Case report	1	42	1 (100)	Silicone	Cosmetic dissatisfaction	1 (100)	Excision + flap	1 (100)	6

in keeping with sclerosing lipogranuloma (Fig. 2). No malignancy was detected in any of the samples.

Outcomes of systematic review

The search retrieved 887 articles (Supplementary Fig. 1). Overall 68 studies [5, 9–12, 14, 15, 18–78] were included for analysis, which included 48 case reports (up to 2 patients), 15 case series (up to 11 patients), 1 prospective study and 5 retrospective studies (Table 3). A total of 918 men of age 17 to 77 years, with a follow-up of 1 day to 34 months were analysed. The most common substance injected was paraffin, $n = 112$ (47.7%) out of 235 patients with data, and the second commonest substance was silicone, $n = 37$ (15.8%). The time between injection and presentation was 1 day to 40 years and a majority of patients ($n = 715$, 77.9%) presented with pain, swelling or penile deformity. Phimosis or paraphimosis was reported in 15 (1.6%) men, Fournier's gangrene occurred in 1 patient, and squamous cell carcinoma was revealed in 1 specimen. The majority ($n = 723$, 78.8%) of patients underwent surgical treatment, whilst 195 (21.2%) men were managed conservatively. Surgical treatments are summarised in Table 3, which included excision and primary closure with or without the use of skin grafts ($n = 615$, 85.1% of all procedures), the use of flaps ($n = 89$, 12.3%) and penile amputation ($n = 2$). The country with the highest number of reported complications was Thailand–Myanmar (71.4%) (Fig. 3).

DISCUSSION

Here we report the complications following male genitalia injection of foreign substances for augmentation, and our experience with managing these cases. In our study period, we had 35 patients presenting with complications, and most men were young (mean age, 36.9 years) and sexually active. Visible lumps and penile deformity resulting in cosmetic dissatisfaction occurred in 57.1% of our patients, and pain and swelling were reported in 45.7%. These were the most common presentations identified in our series, and a majority of patients (77.9%) from our systematic review also presented with pain, swelling or penile deformity. The most common products used for injection in our patients were silicone (45.7%) and liquid paraffin (22.9%). These two agents were also the most injected products identified in our systematic review. The timing of presentation varied and may be a number of years (up to 20 years) following injection when chronic inflammation and sclerosing lipogranuloma had developed. However, acute complications may occur resulting in necrosis which requires immediate debridement. We encountered three cases of necrosis which required acute surgery.

The ultimate aim of treatment is to manage patients' symptoms, prevent progression and provide the best cosmetic and functional outcomes for patients. Reconstructive surgery is associated with risks that patients must be fully informed about. When skin grafts are used, depending on the patient's risk factors (e.g., immunosuppression, smoking, diabetes), there are associated risks and complications when grafting on poorly vascularised beds.

The treatment depends on which area has been injected or involved, patients' symptoms and the patients' expected outcomes. For treatment selection, we recommend MRI penis/scrotum before embarking on any surgical approach. We excise abnormal or necrotic tissue and try to minimise removing any normal skin. Where there has been excessive skin excision, penile reconstruction is performed with fenestrated split-thickness skin graft or full-thickness skin graft. In severe scrotal lymphoedema, we tend to perform a scrotoectomy or "Batman" scrotoectomy. The latter involves a "Batman" shape incision and creation of a neo-scrotum using the lateral scrotal flaps. This technique was described in a previous publication [79]. If there is a loss of penis

Table 3. continued

Author	Date	Country	Study design	No. of patients	Age (years)	Penis	Penis and scrotum	Substance	Presentation/complication	Time to presentation (year)	Surgical management	Conservative management	Follow-up (months)
Arthaud [77]	1973	USA	Case report	1	51	0 (0)	1 (100)	Silicone	Erectile dysfunction	1 (100)	Excision + closure	0 (0)	8
May [78]	1956	USA	Case report	1	37	1 (100)	0 (0)	Paraffin	Pain	1 (100)	Excision + scrotal flap	0 (0)	2
									Penile deformity	1 (100)			
									Sexual dysfunction	1 (100)			

SSG split skin graft, FTSG full-thickness skin graft.




Fig. 3 World map showing geographical distribution of reported cases.

in severe cases from autoamputation or necrosis, a phalloplasty at a later stage can be considered following initial debridement.

In our series, the majority were managed with primary excision and closure (62.3%). Our systematic review showed that 85.1% of all procedures were excision with primary closure with or without a graft. In our series, excision with or without grafting consisted of 73.8% of all procedures.

In those who have penile and scrotal involvement, we tend to treat them separately and perform surgery in a staged approach, treating one area first and the other area at a later date. Overall, we had 11 men who were injected into their penis and scrotum and underwent staged procedures. A stepwise surgical approach, by treating the most problematic/symptomatic part first allows wound healing before moving on to other parts of the genitalia. Often wound healing can be problematic in the management of these patients and by following a stepwise approach we can reduce wound complications. In addition, treating the scrotal lymphoedema first may improve the penile lymphoedema and hence avoid further surgery.

Downey et al. described the geographical distribution of reported cases and found that the highest incidence of reported cases was in Korea (31.7%), followed by Bulgaria (19.8%) and Hungary (14.3%). Our systematic review demonstrated that the current country with the highest number of reported complications was in Thailand-Myanmar (71.4%), this was due to the fact that the largest case series being from there [29].

The largest series identified from our search consisted of 680 men managed during a 5-year period in Thailand-Myanmar [29]. Similar to our study, the majority of patients presented with pain (84%) or swelling (82.5%). Overall, 507 (74.6%) patients required surgical treatment, which included circumcision in 4, and excision with or without graft in 503 men [29]. At the time of analysis, our series on complications represents the largest in the UK, and the second largest in the world. Shin et al. also reported a series size similar to ours, consisting of 34 patients [41]. They evaluated their surgical repair outcomes during a 6-year period comparing a T-type versus a "new" inverted V-type flap reconstruction technique and found that the latter was associated with lower rates of delayed wound healing (V-type 21.4% vs T-type 100%) and wound infection (V-type 7.1% vs T-type 100%) [41].

Limitations

A limitation of our study is the retrospective design and the possibility of not identifying all patients from the search of our

databases. In addition, the reported functional outcomes and patient satisfaction were inconsistently documented in case notes, therefore resulting in only small numbers with inconsistent data which precluded any meaningful analyses. With regard to the systematic review, our search terms may not have captured all relevant studies. A risk of bias assessment of the 68 included reports was not performed. Majority of the included studies were case reports and the reporting of outcomes amongst the included studies was heterogenous which precluded any statistical analyses.

CONCLUSION

Unregulated genitalia injection for aesthetic purposes is becoming popular worldwide. Most products are non-prescribed and are readily available. Patients need to be made aware of the potential complications and the possibility of multiple surgeries to manage any complications. Complications may be severe including tissue necrosis and autoamputation. Referral to a specialist centre for excision of abnormal tissue and reconstruction is recommended to provide the best cosmetic outcomes for this group of young and sexually active men. Apart from penile injections, there are other non-surgical and surgical approaches to augmentation that provide an alternative option for patients. In Schifano et al.'s review, it was highlighted that a multidisciplinary approach is recommended for patients who seek medical advice for penile size concerns. This may require input from surgeons, psychiatrists and psychologists [80]. Education and awareness of this practice in addition to targeted regulation of such practices as well as prevention in public health agencies in communities where the practice appears to be more prevalent is paramount to prevent further morbidity.

DATA AVAILABILITY

The datasets generated during and/or analysed during the current study are available from the corresponding author upon reasonable request.

REFERENCES

1. Ghanem H, Glinas S, Assalian P, Buvat J. Position paper: Management of men complaining of a small penis despite an actually normal size. *J Sex Med.* 2013;10:294–303.
2. Salloom A, Bazzi N, Haber R. Nonsurgical methods for penile augmentation: a systematic review. *Dermatol Surg.* 2021;47:e81–5.

3. Romero-Otero J, Manfredi C, Ralph D, Osmonov D, Verze P, Castiglione F, et al. Non-invasive and surgical penile enhancement interventions for aesthetic or therapeutic purposes: a systematic review. *BJU Int*. 2021;127:269–91.
4. García Gómez B, Alonso Isa M, García Rojo E, Fiorillo A, Romero, Otero J. Penile length augmentation surgical and non-surgical approaches for aesthetical purposes. *Int J Impot Res*. 2022;34:332–6.
5. Quan Y, Gao ZR, Dai X, Kuang L, Zhang M, Li Q, et al. Complications and management of penile augmentation with hyaluronic acid injection. *Asian J Androl*. 2021;23:392–5.
6. Yang DY, Ko K, Lee SH, Moon DG, Kim JW, Lee WK. Efficacy and safety of a newly developed polylactic acid microsphere as an injectable bulking agent for penile augmentation: 18-months follow-up. *Int J Impot Res*. 2017;29:136–41.
7. Casavantes L, Lemperle G, Morales P. Penile girth enhancement with polymethylmethacrylate-based soft tissue fillers. *J Sex Med*. 2016;13:1414–22.
8. Kang DH, Chung JH, Kim YJ, Lee HN, Cho SH, Chang TH, et al. Efficacy and safety of penile girth enhancement by autologous fat injection for patients with thin penises. *Aesthetic Plast Surg*. 2012;36:813–8.
9. Shamsodini A, Al-Ansari AA, Talib RA, Alkhafaji HM, Shokeir AA, Toth C. Complications of penile augmentation by use of nonmedical industrial silicone. *J Sex Med*. 2012;9:3279–83.
10. Ahmed U, Freeman A, Kirkham A, Ralph DJ, Minhas S, Muneer A. Self injection of foreign materials into the penis. *Ann R Coll Surg Engl*. 2017;99:e78–82.
11. Nabiha Ahmad Shariffuddin FA, Xeng Inn F, Mohd Nor F, Hud Muhammad Zin M. Massive penile lipogranuloma following olive oil injections. *Med J Malaysia*. 2021;76:774–6.
12. Nyirády P, Kelemen Z, Kiss A, Bánfi G, Borka K, Romics I. Treatment and outcome of vaseline-induced sclerosing lipogranuloma of the penis. *Urology*. 2008;71:1132–7.
13. Soebhali B, Felicio J, Oliveira P, Martins FE. Sclerosing lipogranuloma of the penis: a narrative review of complications and treatment. *Transl Androl Urol*. 2021;10:2705–14.
14. Sung Kim J, Seob Shin Y, Kwan, Park J. Penile skin preservation technique for reconstruction surgery of penile paraffinoma. *Investig Clin Urol*. 2019;60:133–7.
15. Downey AP, Osman NI, Mangera A, Inman RD, Reid SV, Chapple CR. Penile paraffinoma. *Eur Urol Focus*. 2019;5:894–8.
16. Ahn ST, Il Kwak T, Park KS, Kim JJ, Moon DG. Complications of glans penis augmentation. *Int J Impot Res*. 2019;31:245–55.
17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol*. 2008;61:344–9.
18. Hrudka J, Hojný J, Leamerová E, Matěj R. Giant cell fibroblastoma: a case report. *Cesk Patol*. 2022;58:161–5.
19. Ismy J, Amirsyah M, Palgunadi IN, Firdaus GI, Fakhruulrizal F, Khalilullah SA. One-stage reconstruction of penile paraffinoma using spiral stitches FTSG and evaluation of sexual function. *Plast Reconstr Surg Glob Open*. 2022;10:E4048.
20. Pereira-Lourenço M, Vieira e Brito D, Godinho R, Rabaça C. Giant penis paraffinoma. *Rev Int Androl*. 2021;19:213–6.
21. Khor NWM, Dhar A, Cameron-Strange A. The perils of penile enhancement: case report of a fulminant penile infection. *BMC Urol*. 2021;21:115.
22. Yamasaki Y, Asai A, Maruta S, Sakaguchi M, Tsurusaki T. [A case of glans penile necrosis due to hyaluronic acid into the penis for male genital augmentation]. *Hinyokika Kyo*. 2021;67:399–401.
23. Boucher F, Bayoux R, Allepot K, Braye F, Mojallal A, Morel-Journel N, et al. The bilateral scrotal flap: anatomical study and its use for the management of inflammatory granulomas following custom-made injections. *Ann Chir Plast Esthet*. 2021;66:459–65.
24. Baird Bryce A, Robertson N, Broderick, Gregory A. Penile girth injection complications: a case report. *Sex Med*. 2021;9:100445.
25. Dunev V, Vladislav M, Pencho G. Early result of meshed split-thickness skin graft in patient with paraffinoma of penis. *Urol Case Rep*. 2020;34:101499.
26. Dellis AE, Arkoumanis T, Kyprianou C, Papatouris AG. Paraffinoma, siliconoma and Co: disastrous consequences of failed penile augmentation—a single-centre successful surgical management of a challenging entity. *Andrologia*. 2018;50:e13109.
27. Furr J, Hebert K, Gelman J. Complications of genital enlargement surgery. *J Sex Med*. 2018;15:1811–7.
28. Faveret PLS, Santiago F. Surgical management of penile lesions secondary to foreign body reaction: a case report and systematic review. *Aesthetic Surg J*. 2018;38:770–80.
29. Svensøy JN, Travers V, Osther PJS. Complications of penile self-injections: investigation of 680 patients with complications following penile self-injections with mineral oil. *World J Urol*. 2018;36:135–43.
30. Chon W, Koo JY, Park MJ, Choi K-U, Park HJ, Park NC. Paraffin granuloma associated with buried glans penis-induced sexual and voiding dysfunction. *World J Mens Health*. 2017;35:129.
31. Morales-Raya C, Calleja-Algarra A, Tous-Romero F, Rivera-Díaz R. Penile paraffinoma: should we perform ultrasound? *Actas Dermosifiliogr*. 2017;108:478–80.
32. Alcalde-Alonso M, Velasco-Albendea F, Soto-Díaz A, Gómez-Avivar P, Torres-Gómez F. Paraffinoma of the penis and scrotum (sclerosing granuloma of the male genitalia). *Indian J Dermatol Venereol Leprol*. 2017;83:75–7.
33. Tsili A, Xiropotamou O, Nomikos M, Argyropoulou M. Silicone-induced penile sclerosing lipogranuloma: magnetic resonance imaging findings. *J Clin Imaging Sci*. 2016;6:3.
34. Singh M, Singh V, Lei Chang Moh C. Penile paraffinoma. *Med J Malaysia*. 2015;70.
35. Cormio L, Di Fino G, Scavone C, Selvaggio O, Massenio P, Sanguedolce F, et al. Magnetic resonance imaging of penile paraffinoma: case report. *BMC Med Imaging*. 2014;14:39.
36. Francis J, Choo APC, Khin-Lin GW. Ultrasound and MRI features of penile augmentation by “Jamaica Oil” injection. A case series. *Med Ultrason*. 2014;16:372–6.
37. Majedah S, Hanafiah M, Awang MK. MRI findings of penile paraffinoma. *BMJ Case Rep*. 2014;2014:bcr2014205448.
38. Gómez-Armayones S, Penín RM, Marcoval J. Penile paraffinoma. *Actas Dermosifiliogr*. 2014;105:957–9.
39. Kim SW, Yoon BI, Ha US, Kim SW, Cho YH, Sohn DW. Treatment of paraffin-induced lipogranuloma of the penis by bipedicle scrotal flap with Y-V incision. *Ann Plast Surg*. 2014;73:692–5.
40. De Sati M, Selvaggio O, Di Fino G, Liuzzi G, Massenio P, Sanguedolce F, et al. An unusual delayed complication of paraffin self-injection for penile girth augmentation. *BMC Urol*. 2013;13:66.
41. Shin YS, Zhao C, Park JK. New reconstructive surgery for penile paraffinoma to prevent necrosis of ventral penile skin. *Urology*. 2013;81:437–41.
42. Oanta A, Irimie M, Rogoz S, Oanta S, Lupu S. Penile paraffinomas after self-injection with Kanamycin ointment. *Bull Transilv Univ Brasov*. 2013;6:35–8.
43. Sukop A, Heracek J, Mestak O, Borsky J, Bayer J, Schwarzmanna K. Penis augmentation by application of silicone material: complications and surgical treatment. *Acta Chir Plast*. 2013;55:31–3.
44. Sejben Drl, Rácz A, Svébis M, Patyi M, Cserni G. Petroleum jelly-induced penile paraffinoma with inguinal lymphadenitis mimicking incarcerated inguinal hernia. *Can Urol Assoc J*. 2012;6:E137–9.
45. Bayraktar N, Başar I. Case report penile paraffinoma. *Case Rep Urol*. 2012;2012:202840.
46. Oñate Celdran J, Sanchez Rodriguez C, Tomas Ros M, Miguel Gonzalez Valverde F, Pedro Morga Egea J, Ruiz Marin M, et al. Penile paraffinoma after subcutaneous injection of paraffin. Treatment with a two step cutaneous plasty of the penile shaft with scrotal skin. *Arch Esp Urol*. 2012;65:575–8.
47. Inn FX, Imran FH, Ali MF, Rizuana IH, Zulkifli Z. Penile augmentation with resultant foreign material granuloma and sequelae. *Malays J Med Sci*. 2012;19:81.
48. Karakan T, Ersoy E, Hacıoğlu M, Özgür BC, Özcan S, Aydın A. Injection of vaseline under penis skin for the purpose of penis augmentation. *Case Rep Urol*. 2012;2012:1–2.
49. Kadouch JA, Van Rozelaar L, Kanhai RJC, Sawor JH, Karim RB. Complications of penis or scrotum enlargement due to injections with permanent filling substances. *Dermatol Surg*. 2012;38:1244–50.
50. Bachmeyer C, Moguelet P, Gombeaud T, Sbidian E, Aractingi S. Penile paraffinoma developing during treatment with pegylated interferon alfa-2a for chronic hepatitis C virus infection. *Arch Dermatol*. 2011;147:1232–3.
51. Manny T, Pettus J, Hemal A, Marks M, Mirzazadeh M. Penile sclerosing lipogranulomas and disfigurement from use of “1Super Extenze” among Laotian immigrants. *J Sex Med*. 2011;8:3505–10.
52. Foxton G, Vinciullo C, Tait CP, Sinniah R. Sclerosing lipogranuloma of the penis. *Australas J Dermatol*. 2011;52:e12–4.
53. Bobik O Jr, Bobik SRO. Penile paraffinoma and ulcers of penis. *Bratisl Lek List*. 2011;112:653–4.
54. Al-Ansari AA, Shamsodini A, Talib RA, Gul T, Shokeir AA. Subcutaneous cod liver oil injection for penile augmentation: review of literature and report of eight cases. *Urology*. 2010;75:1181–4.
55. Bjurlin MA, Carlsen J, Grevius M, Jordan MD, Taylor A, Divakaruni N, et al. Mineral oil-induced sclerosing lipogranuloma of the penis. *J Clin Aesthet Dermatol*. 2010;3:41.
56. Pónyai K, Marschalkó M, Hársing J, Ostorházy E, Kelemen Z, Nyirády P, et al. Paraffinoma. *J Dtsch Dermatol Ges*. 2010;8:686–8.
57. Picozzi SCM, Carmignani L. Paraffinoma of the penis. *Int J Emerg Med*. 2010;3:507–8.

58. Shaeer O, Shaeer K. Delayed complications of gel injection for penile girth augmentation. *J Sex Med.* 2009;6:2072–8.
59. Silberstein J, Downs T, Goldstein I. Penile injection with silicone: case report and review of the literature. *J Sex Med.* 2008;5:2231–7.
60. Pehlivanov G, Kavaklieva S, Kazandjieva J, Kapnilov D, Tsankov N. Foreign-body granuloma of the penis in sexually active individuals (penile paraffinoma). *J Eur Acad Dermatol Venereol.* 2008;22:845–51.
61. Dachlan IDI. Penile granuloma caused by liquid silicone injection. *J Med Sci (Berk Ilmu Kedokt).* 2007;39:53–8.
62. Oh KJ, Park K, Kang TW, Kwon DD, Ryu SB. Subcutaneous metallic mercury injection for penile augmentation. *Urology.* 2007;69:185.e3–185.e4.
63. Lee SW, Bang CY, Kim JH. Penoscrotal reconstruction using groin and bilateral superomedial thigh flaps: a case of penile vaselinoma causing Fournier's gangrene. *Yonsei Med J.* 2007;48:723–6.
64. Rosenberg E, Romanowsky I, Asali M, Kaneti J. Three cases of penile paraffinoma: a conservative approach. *Urology.* 2007;70:372.e9–372.e10.
65. Eandi JA, Yao AP, Javidan J. Penile paraffinoma: the delayed presentation. *Int Urol Nephrol.* 2007;39:553–5.
66. Akkus E, Iscimen A, Tasli L, Hattat H. Paraffinoma and ulcer of the external genitalia after self-injection of vaseline. *J Sex Med.* 2006;3:170–2.
67. Cavalcanti AG, Hazan A, Favorito LA. Surgical reconstruction after liquid silicone injection for penile augmentation. *Plast Reconstr Surg.* 2006;117:1660–1.
68. Hohaus K, Bley B, Köstler E, Schönlebe J, Wollina U. Mineral oil granuloma of the penis. *J Eur Acad Dermatol Venereol.* 2003;17:585–7.
69. Choudhury N, Frame JD, Lewi HJE. Penile paraffinoma and a novel treatment. *BJU Int.* 2003;92:e14.
70. Santos P, Chaveiro A, Nunes G, Fonseca J, Cardoso J. Penile paraffinoma. *J Eur Acad Dermatol Venereol.* 2003;17:583–4.
71. Cohen JL, Keoleian CM, Krull EA. Penile paraffinoma: self-injection with mineral oil. *J Am Acad Dermatol.* 2002;47:5251–3.
72. Kalsi JS, Arya M, Peters J, Minhas S, Ralph DJ. Grease-gun injury to the penis. *J R Soc Med.* 2002;95:254.
73. Steffens J, Kosharsky B, Hiebl R, Schönberger B, Röttger P, Loening S. Paraffinoma of the external genitalia after autoinjection of vaseline. *Eur Urol.* 2000;38:778–81.
74. Ciancio SJ, Coburn M. Penile salvage for squamous cell carcinoma associated with mineral oil injection. *J Urol.* 2000;164:1650.
75. Murano G, Dami A, Farina U. Paraffinoma of the penis: one-stage repair. *Arch Esp Urol.* 1996;49:648–50.
76. Wassermann RJ, Greenwald DP, Gorney M. Debilitating silicone granuloma of the penis and scrotum. *Ann Plast Surg.* 1995;35:505–10.
77. Arthaud JB. Silicone-induced penile sclerosing lipogranuloma. *J Urol.* 1973;110:210.
78. May JA, Pickering PP. Paraffinoma of the penis. *Calif Med.* 1956;85:42.
79. Alnajjar HM, Castiglione F, Ahmed K, Haider A, Nigam R, Muneer A. A novel "Batman" scrotoectomy technique for the management of scrotal lymphoedema following treatment for penile cancer. *Transl Androl Urol.* 2019;8:448–56.
80. Schifano N, Cakir OO, Castiglione F, Montorsi F, Garaffa G. Multidisciplinary approach and management of patients who seek medical advice for penile size concerns: a narrative review. *Int J Impot Res.* 2022;34:434–51.

ACKNOWLEDGEMENTS

AM acknowledges support from the NIHR Biomedical Research Centre, University College London Hospital.

AUTHOR CONTRIBUTIONS

Conceived and/or designed the work that led to the submission, acquired data, and/or played an important role in interpreting the results: all authors. Drafted or revised the manuscript: KHP, HMA. Approved the final version: all authors. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: KHP, HMA.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41443-023-00675-8>.

Correspondence and requests for materials should be addressed to Hussain M. Alnajjar.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023